Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases

Table 6 Results of multivariate Cox regression analysis

Influential factors (independent variables)	P value	HR	95%CI for HR
			Lower bound	Upper bound
KPS score (≥ 70/< 70)	0.049a	5.452	1.008	29.479
Oligometastatic liver disease (yes/no)	0.156	0.592	0.286	1.222
Distant lymph node metastasis (yes/no)	0.843	1.046	0.670	1.633
Pre-hepatic metastasis targeted therapy (yes/no)	0.378	1.853	0.470	7.310
Hepatic lobe involvement
Bilateral lobes, dummy variable	0.449
Left-sided lobe	0.736	0.858	0.353	2.088
Right-sided lobe	0.206	0.686	0.382	1.231
Chemotherapy regimen
Taxane-based ± platinum, dummy variable	0.187
Fluoropyrimidine ± platinum	0.498	0.849	0.528	1.363
Other	0.123	1.570	0.885	2.785
Chemotherapy cycle (≥ 4/< 4)	< 0.001a	0.139	0.072	0.266
Immunotherapy cycle (≥ 4/< 4)	< 0.001a	0.225	0.132	0.383
Liver local treatment (yes/no)	0.021a	0.549	0.330	0.913

^aP < 0.05, statistical significance.

HR: Hazard ratio; 95%CI: 95% confidence interval; KPS: Karnofsky Performance Status.